A prospective, non-interventional, multinational, observational study with isatuximab in patients with relapsed and/or refractory multiple myeloma (RRMM)

PI: Troy H. Guthrie, Jr.

Disease

  • Multiple Myeloma

Contact

North Florida / Jacksonville: Rhonda Calhoun (904) 427-1217

Topics

  • Multiple Myeloma

Sponsors

Sanofi

Number

OBS16577

Study Summary:
This study will provide evidence on the characteristics of patients treated with isatuximab, when approved, in the RW setting, likely as part of combination therapy (with pomalidomide and dexamethasone or with carfilzomib and dexamethasone) and will shed light on treatment strategies utilized in daily clinical practice and their effectiveness and safety outcomes; the impact of which on patients’ QoL will be an important factor in interpreting differences in prognosis and outcomes in varying patient groups with RRMM.